Revmalgyn (meloxicam) rectal suppositories 15 mg. №5

$8.70

Manufacturer: Ukraine

Purpose: Meloxicam treats rectal pain and inflammation by inhibiting prostaglandins.

SKU: MED60972 Category:

Description

Revmalgyn (meloxicam) Rectal Suppositories 15 mg. №5

Ingredients:

Each rectal suppository contains 15 mg of meloxicam as the active ingredient.

Dosage:

The recommended dosage is one rectal suppository (15 mg) daily. Consult your healthcare provider for personalized dosing instructions.

Indications:

Revmalgyn rectal suppositories are indicated for the relief of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.

Contraindications:

Do not use Revmalgyn suppositories if you are allergic to meloxicam or have a history of allergic reactions to NSAIDs. Avoid use in patients with active gastrointestinal bleeding or severe renal impairment.

Directions:

Insert one suppository into the rectum and retain for as long as possible for optimal absorption. Follow the instructions provided in the package insert.

Scientific Evidence:

Meloxicam, the active ingredient in Revmalgyn suppositories, is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacological effects by inhibiting cyclooxygenase enzymes, thereby reducing the production of pro-inflammatory prostaglandins. Studies have demonstrated the efficacy of meloxicam in the management of pain and inflammation associated with various arthritic conditions.

Additional Information:

It is important to note that NSAIDs, including meloxicam, may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Patients with a history of cardiovascular disease or risk factors should use meloxicam with caution and under close medical supervision.

Clinical trials have shown that rectal administration of meloxicam can provide rapid and effective pain relief in patients who may have difficulty swallowing oral medications or experience gastrointestinal side effects with oral NSAIDs.